April 26th, 2011
Drug-Eluting Stents Add Nearly $1.6 Billion per Year to Medicare Costs
Larry Husten, PHD
Drug-eluting stents (DESs) cost Medicare an additional $1.57 billion per year, according to a study published online in the Archives of Internal Medicine. Using a random sample of Medicare beneficiaries, Peter Groeneveld and colleagues compared annual costs for patients with coronary artery disease in 2002 (the year before DESs were introduced) with costs from 2002 […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?